Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemia.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
15 04 2021
Historique:
received: 23 09 2020
accepted: 05 04 2021
entrez: 16 4 2021
pubmed: 17 4 2021
medline: 19 11 2021
Statut: epublish

Résumé

T cell prolymphocytic leukemia (T-PLL) is a rare disease with aggressive clinical course. Cytogenetic analysis, whole-exome and whole-genome sequencing have identified primary structural alterations in T-PLL, including inversion, translocation and copy number variation. Recurrent somatic mutations were also identified in genes encoding chromatin regulators and those in the JAK-STAT signaling pathway. Epigenetic alterations are the hallmark of many cancers. However, genome-wide epigenomic profiles have not been reported in T-PLL, limiting the mechanistic study of its carcinogenesis. We hypothesize epigenetic mechanisms also play a key role in T-PLL pathogenesis. To systematically test this hypothesis, we generated genome-wide maps of regulatory regions using H3K4me3 and H3K27ac ChIP-seq, as well as RNA-seq data in both T-PLL patients and healthy individuals. We found that genes down-regulated in T-PLL are mainly associated with defense response, immune system or adaptive immune response, while up-regulated genes are enriched in developmental process, as well as WNT signaling pathway with crucial roles in cell fate decision. In particular, our analysis revealed a global alteration of regulatory landscape in T-PLL, with differential peaks highly enriched for binding motifs of immune related transcription factors, supporting the epigenetic regulation of oncogenes and genes involved in DNA damage response and T-cell activation. Together, our work reveals a causal role of epigenetic dysregulation in T-PLL.

Identifiants

pubmed: 33859327
doi: 10.1038/s41598-021-87890-9
pii: 10.1038/s41598-021-87890-9
pmc: PMC8050249
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

8318

Subventions

Organisme : NCI NIH HHS
ID : K23 CA160345
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA015083
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA097274
Pays : United States

Références

Nat Med. 2016 Jun;22(6):632-40
pubmed: 27135738
Nature. 2014 Mar 27;507(7493):455-461
pubmed: 24670763
Cell Rep. 2017 Oct 17;21(3):784-797
pubmed: 29045844
Bioinformatics. 2007 Jan 15;23(2):257-8
pubmed: 17098774
Nat Med. 2014 Oct;20(10):1130-7
pubmed: 25194570
F1000Res. 2016 Jun 20;5:1438
pubmed: 27508061
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Br J Haematol. 2016 Apr;173(2):265-73
pubmed: 26917488
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Blood. 2014 Aug 28;124(9):1460-72
pubmed: 24825865
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Nat Genet. 2019 Oct;51(10):1494-1505
pubmed: 31570894
Blood. 2009 Nov 19;114(21):4675-86
pubmed: 19770358
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Nat Biotechnol. 2010 Oct;28(10):1045-8
pubmed: 20944595
Nature. 2012 Jan 04;481(7381):389-93
pubmed: 22217937
Genes Chromosomes Cancer. 2016 Jan;55(1):82-94
pubmed: 26493028
Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3118-23
pubmed: 14973184
J Cancer. 2015 Jul 16;6(9):877-82
pubmed: 26284139
Blood. 2017 Nov 23;130(21):2326-2338
pubmed: 28978570
BMC Genomics. 2014 Apr 15;15:284
pubmed: 24735413
Nat Genet. 2017 Aug;49(8):1211-1218
pubmed: 28671688
Cancer Cell. 2017 Jul 10;32(1):27-41.e4
pubmed: 28625481
EMBO J. 2012 Nov 14;31(22):4318-33
pubmed: 23064151
Cell. 2013 Nov 7;155(4):934-47
pubmed: 24119843
Nucleic Acids Res. 2011 Jan;39(Database issue):D691-7
pubmed: 21067998
Haematologica. 2012 Mar;97(3):328-30
pubmed: 22383743
Nat Genet. 2016 Oct;48(10):1193-203
pubmed: 27526324
Nat Commun. 2018 Dec 17;9(1):5344
pubmed: 30559442
BMC Bioinformatics. 2014 Aug 15;15:280
pubmed: 25128017
Nature. 2015 Feb 19;518(7539):317-30
pubmed: 25693563
Cell. 2016 Nov 17;167(5):1369-1384.e19
pubmed: 27863249
Front Oncol. 2018 Jun 27;8:229
pubmed: 29998084
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Bioinformatics. 2010 Apr 1;26(7):873-81
pubmed: 20147302
Genome Biol. 2008;9(9):R137
pubmed: 18798982
Blood. 2012 Aug 23;120(8):1613-23
pubmed: 22645177
Genes Dev. 2013 Dec 15;27(24):2648-62
pubmed: 24285714
Front Oncol. 2018 Mar 29;8:92
pubmed: 29651407
BMC Bioinformatics. 2013 Mar 09;14:91
pubmed: 23497356
Proc Natl Acad Sci U S A. 2017 Apr 4;114(14):E2911-E2919
pubmed: 28314854
Br J Pharmacol. 2017 Dec;174(24):4701-4715
pubmed: 28703283
Cancer Discov. 2015 Oct;5(10):1058-71
pubmed: 26229090
Nature. 2015 Feb 19;518(7539):337-43
pubmed: 25363779
BMC Genomics. 2017 Dec 21;18(1):985
pubmed: 29268714
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Nat Commun. 2016 Sep 28;7:12983
pubmed: 27677335
Nature. 2012 Oct 25;490(7421):543-6
pubmed: 22992523
Haematologica. 2013 Feb;98(2):269-73
pubmed: 22875623
Nat Commun. 2014 Sep 30;5:5114
pubmed: 25268989
Blood. 2012 Jan 5;119(1):180-7
pubmed: 22065599
Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):E4946-53
pubmed: 25369933
Sci Transl Med. 2015 Jun 24;7(293):293ra102
pubmed: 26109102
Nucleic Acids Res. 2016 Jan 4;44(D1):D1023-31
pubmed: 26590405
Mol Biosyst. 2016 Feb;12(2):477-9
pubmed: 26661513
Cancer Discov. 2017 Mar;7(3):322-337
pubmed: 28069569
Cold Spring Harb Perspect Biol. 2010 Jun;2(6):a000109
pubmed: 20516126
Nat Commun. 2018 Feb 15;9(1):697
pubmed: 29449575
Front Oncol. 2018 Aug 13;8:317
pubmed: 30151355

Auteurs

Shulan Tian (S)

Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. tian.shulan@mayo.edu.

Henan Zhang (H)

Department of Urology, Mayo Clinic, Rochester, MN, USA.

Pan Zhang (P)

Division of Information Management and Analytics, Department of Information Technology, Mayo Clinic, Rochester, MN, USA.
Illinois Informatics Institute, University of Illinois at Urbana-Champaign, Urbana, IL, USA.

Michael Kalmbach (M)

Division of Information Management and Analytics, Department of Information Technology, Mayo Clinic, Rochester, MN, USA.

Jeong-Heon Lee (JH)

Division of Experimental Pathology and Laboratory Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

Tamas Ordog (T)

Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA.

Paul J Hampel (PJ)

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Timothy G Call (TG)

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Thomas E Witzig (TE)

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Neil E Kay (NE)

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Eric W Klee (EW)

Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

Susan L Slager (SL)

Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

Huihuang Yan (H)

Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

Wei Ding (W)

Division of Hematology, Mayo Clinic, Rochester, MN, USA. Ding.Wei@mayo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH